Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of EDP-978 in Healthy Adults
NCT07540910Phase 1Recruiting
- Sponsor
- Enanta Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EPS-978 in chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU) (4 arms), sponsored by Enanta Pharmaceuticals. Primary endpoint: Adverse Events up to 28 Days. Started Apr 2026; status: recruiting.
02
Drugs
EPS-978
03
Conditions
chronic inducible urticaria (CIndU)chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT07540910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540910.